A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group
2009 ◽
Vol 45
(5)
◽
pp. 782-788
◽
2014 ◽
Vol 50
(13)
◽
pp. 2336-2350
◽
2000 ◽
Vol 119
(4)
◽
pp. 804-813
◽
1997 ◽
Vol 123
(11-12)
◽
pp. 652-658
◽
2014 ◽
Vol 40
(9)
◽
pp. 1136-1142
◽